Share-based Payment Arrangement, Expense of Cullinan Therapeutics, Inc. from 31 Dec 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Cullinan Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2020 to 30 Sep 2025.
  • Cullinan Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $9,467,000, a 0.39% increase year-over-year.
  • Cullinan Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $38,362,000, a 7.4% increase year-over-year.
  • Cullinan Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $37,824,000, a 24% increase from 2023.
  • Cullinan Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $30,438,000, a 8.9% increase from 2022.
  • Cullinan Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $27,957,000, a 15% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Cullinan Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $38,362,000 $9,467,000 +$37,000 +0.39% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $38,325,000 $9,887,000 -$646,000 -6.1% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $38,971,000 $9,374,000 +$1,147,000 +14% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $37,824,000 $9,634,000 +$2,115,000 +28% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $35,709,000 $9,430,000 +$1,690,000 +22% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $34,019,000 $10,533,000 +$2,613,000 +33% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $31,406,000 $8,227,000 +$968,000 +13% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $30,438,000 $7,519,000 +$6,000 +0.08% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $30,432,000 $7,740,000 +$2,469,000 +47% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $27,963,000 $7,920,000 -$688,000 -8% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $28,651,000 $7,259,000 +$694,000 +11% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $27,957,000 $7,513,000 -$4,632,000 -38% 01 Oct 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q3 2022 $32,589,000 $5,271,000 +$714,000 +16% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 $31,875,000 $8,608,000 +$4,443,000 +107% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $27,432,000 $6,565,000 +$3,057,000 +87% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $24,375,000 $12,145,000 01 Oct 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
Q3 2021 $4,557,000 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $4,165,000 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q2
Q1 2021 $3,508,000 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1

Cullinan Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $37,824,000 +$7,386,000 +24% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $30,438,000 +$2,481,000 +8.9% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $27,957,000 +$3,582,000 +15% 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
2021 $24,375,000 +$9,465,000 +63% 01 Jan 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
2020 $14,910,000 01 Jan 2020 31 Dec 2020 10-K 17 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.